A Trial of I/V Arniodarone in Paroxysmal Atrial Fibrillation

Abstract

INTRODUCTION:
Aminodarone, a benzofuran compound, originally manufactured in the pharmacologic laboratories in Belgium in 1962 was recognized as a potent coronary dilator in 1967. That Amidarone might have, a new e1ectrophysiologic profile with respect to cardiac muscle was not appreciated until several years later. ^3,4,27.

RESULTS:

Fourteen, out of fifteen patients converted to sinus rhythm and there was only one failure that remained in atrial fibrillation and infusion was discontinued after 36 hours of treatment.The rest of nine responders weighing from 45 to 75 Kg. were slow to respond, a compared to the first group.

DISCUSSION:

Amiodarone has been used for almost every arrhythmia (with success), either alone or in combination with other antiarrhythmic agents, and a number of side effects ^{20,21,22,23,24,25} and drug interactions ^16,17,18,19 are known.